Makers Laboratories Limited (MAKERSL) fundamentals
Makers Laboratories Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as MAKERSL (ISIN INE987A01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Makers Laboratories Limited does
Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company's segments include Pharmaceutical and Chemical Manufacturing. It has one manufacturing unit in India manufacturing formulations for the Indian market. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimesulide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). It also offers a range of diabetic and hypertensive drugs, including Voglibose, Gli-me range (Glimepiride + Metformin +Pioglitazone), and Hypernorm range (Telmisartan). Its product categories include Inspira - Retail Packs and Experia - Bulk Packs. Its Inspira - Retail Packs include anthelmintics, anti-biotics, anti-emetics and anti-nauseants. Its Experia - Bulk Packs include betamethasone 0.5 mg tablets, chloramphenicol capsules 250 mg and diclofenac 50 mg tablets.
Valuation and market data
| Last close | ₹183.00 |
|---|---|
| Market capitalisation | ₹360 crore |
| Enterprise value | ₹370 crore |
| P/E (TTM) | 45.86 |
| Price to book | 2.94 |
| Price to sales (TTM) | 1.42 |
| Book value per share | ₹62.18 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹51 crore | ₹-2 crore | ₹-2 crore | -2.91 |
| Mar 2025 | ₹54 crore | ₹5 crore | ₹5 crore | 7.87 |
| Mar 2024 | ₹50 crore | ₹-7 crore | ₹-7 crore | -11.78 |
| Mar 2023 | ₹44 crore | ₹-7 crore | ₹-6 crore | -10.58 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 61.3% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.4% |
| Retail and others | 38.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.